Nov 2017: Diagnosed with Stage IV high-risk Neuroblastoma. Nov 2017–Apr 2019: Completed standard treatment; NED. Apr 2019–Apr 2021: Completed DFMO clinical trial. Apr 2022: Relapse. Apr 2022–Jun 2023: Completed relapse treatment; NED again. Jun 2023–Jun 2024: High-dose DFMO (compassionate use) clinical trial. Jun 2024: Second relapse. Jul 2025: NED again. Mar 2026: Relapse.
Monday, April 20, 2026
Quick Update...Treatment Underway
Friday, April 17, 2026
Treatment Plan (Finally)
Caroline has officially met the bloodwork requirements to begin a clinical trial for her fourth fight with Neuroblastoma.
She will start outpatient treatment on Monday at Vanderbilt, receiving a combination of two drugs—one taken orally (an inhibitor) and one administered intravenously (an immunotherapy).
The known and potential side effects include:
- Severe pain from the antibody infusion
- Body rash
- Low blood pressure
- Low oxygen levels
- Neutropenia (a compromised immune system)
- Nausea
- Exhaustion
As far as we know, these treatments should not cause hair loss, which has been Caroline’s “silver lining.” We will once again work closely with her care team to manage and treat side effects as effectively as possible. The infusion portion of treatment carries significant risk—particularly related to blood pressure and oxygen levels—so she will be closely monitored throughout each session. She will also undergo additional testing during this protocol, including EKGs, echocardiograms, urine tests, frequent bloodwork, etc.
The first month of treatment will include a cycle total of 14 days of oral medication 💊 + 3 days of antibody infusion (immunotherapy). She will also receive 5 days of injections at home to help her immune system recover.
Caroline will repeat this same schedule the following month, with disease-status imaging planned for mid-June.
The waiting has been an incredibly anxious time for all of us, so we are very relieved to finally have a plan in place.
We are deeply grateful to the Beat Childhood Cancer (BeatCC) Foundation and Research Consortium for developing these trials, giving kids like Caroline more options in fighting this awful disease. Thank you as well to our friends and family who have supported BeatCC over the years—your generosity truly helps drive critical research and save lives.
We are also incredibly appreciative of our entire Vanderbilt team for partnering with BeatCC to bring these trials to our home hospital. Caroline will (once again!) be the first patient at Vanderbilt to receive this treatment.
Thank you all for your continued support and prayers—we feel them every day.
Love,The Lantz Family
#carolinestrong
Thursday, April 9, 2026
Update(ish)
- The attempt to biopsy the spot on her pelvis was unsuccessful due to the size and because it only showed up on her PET scan, not on the CT, which is what they primarily use to guide the biopsy needle. Therefore, at this time, we have no tissue to send off for sequencing / analysis for any potential precision medicine recommendations.
- The bone marrow biopsy from her lower back was negative for Neuroblastoma - good news / bad news. It hasn’t spread to her marrow yet, but that also means no biopsy results for disease sequencing and targeted therapries.
- Last, but definitely not least, the treatment trial we are trying to enroll her in has strict FDA requirements for labwork ranges/results, which Caroline's body has been unable to meet (despite 4 different lab draws at 2 different locations), so we are not currently able to enroll her.
We will update the blog as soon as we have any relevant information. We're still all struggling to process the news of the relapse, in addition to all of the setbacks. We're so grateful for the messages, gift cards, and most importantly: prayers. Please keep praying.
Love,
#carolinestrong
#ftgf


